Business Development, In-Vitro and In-Vivo - Clinical Research Informer

Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer

The Pharma Data

JANUARY 12, 2021

Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g. Dr. Graham earned an M.D.,

Life Science

Life Science Antibody In-Vivo In-Vitro

Transitioning Between Academia and Industry: Advice from Leading Scientists That Made the Switch

XTalks

OCTOBER 1, 2020

And although academia and industry have often been pitted against each other in the realm of scientific discovery and development, there may be more similarities and synergies between the two than we may think. WeiQi Lin, MD, PhD, executive vice president of research & development and principal scientist, DURECT Corporation.

Scientist

Scientist In-Vitro Research Life Science

Using FDA Product Specific Guidances (PSGs) as a Trigger for Generic Drug Development

Drug Patent Watch

DECEMBER 11, 2024

These guidances serve as a roadmap for companies looking to develop generic versions of brand-name drugs, offering invaluable insights into the FDA’s expectations for demonstrating bioequivalence and ensuring product quality. They provide recommendations on the design of in vitro and in vivo studies.

Generic Drugs

Generic Drugs Production Development Bioequivalency

Clinical Research Informer

Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer

Transitioning Between Academia and Industry: Advice from Leading Scientists That Made the Switch

Using FDA Product Specific Guidances (PSGs) as a Trigger for Generic Drug Development

Webinars

Stay Connected